Skip to main content
. 2019 Aug 16;10:889. doi: 10.3389/fphar.2019.00889

Table 1.

Distribution of demographic and clinical comorbidity data in study cohorts.

Variables ACO p-value
Statin
All (N = 8,654) No (N = 7,443) Yes (N = 1,211)
n % n % n %
Age, years <0.001***
<50 1,599 (18.5) 1,418 (19.1) 181 (15.0)
50–64 2,418 (27.9) 1,962 (26.4) 456 (37.7)
65+ 4,637 (53.6) 4,063 (54.6) 574 (47.4)
Mean (SD)a 64.0 14.8 64.1 15.3 62.9 11.9 0.001**
Gender <0.001***
Women 3,722 43.0 3,090 41.5 632 52.2
Men 4,932 57.0 4,353 58.5 579 47.8
Comorbidity
Sleep disorder 3,578 41.4 2,962 39.8 616 50.9 <0.001***
Diabetes 1,455 16.8 1,093 14.7 362 29.9 <0.001***
Hypertension 5,628 65.0 4,648 62.5 980 80.9 <0.001***
Hyperlipidemia 2,825 32.6 1,898 25.5 927 76.6 <0.001***
CAD 3,576 41.3 2,917 39.2 659 54.4 <0.001***
Stroke 1,415 16.4 1,205 16.2 210 17.3 <0.001***
Hepatitis B 326 3.77 281 3.78 45 3.72 0.92
Hepatitis C 135 1.56 116 1.56 19 1.57 0.98
Medication
Inhaled corticosteroids (ICSs) 2,064 23.9 1,743 23.4 321 26.5 0.02*
Oral steroids (OSs) 6,319 73.0 5,377 72.2 942 77.8 <0.001***

Chi-square test, a t-test.

*P < 0.05, **P < 0.01, ***P < 0.001.